DOCSLIB.ORG

2010Petermacresearchreport.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2010Petermacresearchreport.Pdf Contents Peter MacCallum Cancer Centre CEO’s report 5 1.5 Tumour Angiogenesis program 58 3.2.2 Centre for Cancer Imaging 110 St Andrews Place East Melbourne Victoria 3002 Director’s report 7 1.6 Cancer Therapeutics program 62 3.2.3 Centre for Biostatistics and Clinical Trials 111 Clinical research overview 11 1.6.1 Gene Regulation laboratory 64 Locked Bag 1 A’Beckett Street 3.2.4 Clinical Trials Unit 112 Victoria Australia 8006 About research at Peter Mac 12 1.6.2 Melanoma Research laboratory 65 3.2.5 Clinical Psychology 113 Telephone (03) 9656 1238 Cancer research at a glance 14 1.6.3 Molecular Imaging and Targeted Therapeutics laboratory 66 3.2.6 Familial Cancer Care 114 Facsimile (03) 9656 1411 Metrics 15 1.6.4 Translational Research 3.2.7 Infectious Diseases 115 www.petermac.org/Research Research / Cancer Matrix 16 Laboratory 67 3.2.8 kConFab Follow-Up Project 116 For additional copies of this publication Interdisciplinary Matrix 18 1.6.5 Pfizer/Peter Mac Cancer Genomics 3.2.9 Molecular Pathology laboratory 117 or to provide feedback please contact: Recent research highlights with program 68 Peter Mac Communications and Brand impact on cancer care 19 1.6.6 CCV Venture Grant Initiative 69 3.2.10 Nursing and Supportive Care 118 via [email protected] 1.6.7 CRC for Cancer Therapeutics 3.2.11 Nutrition 119 1 Laboratory Research 20 Front cover: Dr Mark Shackleton, Translational Research laboratory 70 3.2.12 onTrac@Peter Mac 120 Pfizer Australia Research Fellow, 1.1 Cancer Immunology program 24 Head, Melanoma Research laboratory 3.2.13 Pain and Palliative Care 121 1.1.1 Cancer Cell Death laboratory 26 2 Clinical and Translational and medical oncologist, Melanoma Service. Research 72 3.2.14 Pharmacy 122 Below left: Dr Jamie Lopez, 1.1.2 Cellular Immunity laboratory 27 Cancer Medicine 76 3.2.15 Physical Sciences 123 Cancer Immunology program. 1.1.3 Immune Signalling laboratory 28 Below right: Dr Claire Milton, Cancer Surgery 78 3.2.16 Radiation Therapy 124 1.1.4 Immunotherapy laboratory 29 Cancer Cell Biology program. Radiation Oncology and Cancer 3.2.17 Social Work 125 1.1.5 Haematology Immunology Imaging 80 Translational Research laboratory 30 2.1 Medical Oncology and Early Phase 4 Education and Learning 130 1.2 Cancer Genomics program 32 Clinical Trials 82 4.1 Cancer Research Education 1.2.1 Cancer Genetics and 2.2 Breast Service 83 program 133 Genomics laboratory 34 2.3 Gastrointestinal Service 84 4.1.1 Seminar programs 133 1.2.2 Sarcoma Genomics and Genetics laboratory 35 2.4 Gynae-oncology Service 85 4.1.2 Student Training Program 136 1.2.3 Surgical Oncology laboratory 36 2.5 Haematology Service 86 4.1.3 Peter Mac Research Postgraduate Student Society 139 1.2.4 VBCRC Cancer Genetics 2.6 Head and Neck Service 87 4.1.4 Research Awards 140 laboratory 37 2.7 Lung Service 88 4.1.5 Peter Mac Postdoctoral program 142 1.2.5 kConFab 38 2.8 Melanoma and Skin Service 89 4.1.6 Community and School 1.3 Growth Control and 2.9 Paediatrics and Late Effects Service 90 Differentiation program 40 Outreach Activities 143 2.10 Sarcoma Service 91 1.3.1 Growth Control laboratory 42 4.2 Clinical Research Education and 2.11 Uro-oncology Service 92 Training Programs 144 1.3.2 Molecular Oncology laboratory 43 1.3.3 Protein Chemistry laboratory 44 3 Enabling Technologies and 5 Leadership and Governance 146 1.4 Cancer Cell Biology program 46 Interdisciplinary Research 5.1 Research leadership 149 Platforms 96 1.4.1 Cell Cycle and Cancer Genetics 5.2 Cancer Research management 151 laboratory 48 3.1 Enabling Technology Platforms 97 5.3 Governance 152 1.4.2 Cell Cycle Development 3.1.1 Functional Genomics facility 99 5.4 Ethical Conduct of Research 154 laboratory 49 3.1.2 Molecular Genomics facility 100 5.5 Commercialisation 157 1.4.3 Cell Growth and Proliferation 3.1.3 Bioinformatics facility 101 laboratory 50 3.1.4 Flow Cytometry facility 102 1.4.4 Differentiation and Transcription 6 Publications 158 laboratory 51 3.1.5 Microscopy facility 103 1.4.5 Epithelial Stem Cell Biology 3.1.6 Media and Laboratory Services laboratory 52 facility 104 1.4.6 Metastasis Research laboratory 53 3.1.7 Tissue Bank facility 105 1.4.7 Molecular Radiation Biology 3.2 Interdisciplinary Research laboratory 54 Platforms 107 1.4.8 Tumour Suppression laboratory 55 3.2.1 Centre for Blood Cell Therapies 109 As the largest cancer research site in Australia, CEO’s report Peter MacCallum Cancer Centre is a major contributor to advances in cancer diagnosis and treatment. 2010 was a busy and challenging The co-location of a sophisticated research year for research at Peter Mac. facility and a world-class cancer hospital We continued to win competitive creates a highly synergistic combination. grants; our staff distinguished With researchers and clinicians working themselves in many ways; side-by-side, Peter Mac has made significant we streamlined our research contributions to basic research, translational governance framework and we research and clinical trials. worked hard to strengthen our partnerships with other research organisations and to reach out to the community. In addition, a lot of passion, energy Our research staff also contributed Highlights during the year included and time were devoted to articulating a strongly to the strategic discussions the opening of the Victorian Centre vision for the research facilities to be sponsored by the Victorian CCC Joint for Functional Genomics in Cancer incorporated into the Comprehensive Venture; a group comprising the four (supported by a $2.5m grant from the Cancer Centre to be built in Parkville. Parkville building partners (as above), Australian Cancer Research Foundation) plus the Walter and Eliza Hall Institute and the establishment of both the As a major focus in 2010, our research of Medical Research, The Royal Women’s Melanoma Research laboratory, as part staff continued collaborating with Hospital and The Royal Children’s of the Cancer Therapeutics program, colleagues from Melbourne Health, Hospital. This group is charged with and the Tumour Angiogenesis program. the Ludwig Institute for Cancer Research enhancing collaboration amongst the Considerable energy was also devoted (Parkville Branch) and The University seven independent members to produce to further strengthening our focus of Melbourne in advising on the research better outcomes for cancer patients on translational research. facilities that will form part of the Victorian treated at the new facility ... and beyond. Comprehensive Cancer Centre (VCCC). A number of Peter Mac researchers We finished the year with the three Professor Joe Trapani took up his and clinician-researchers were bidding consortia having submitted their appointment as Executive Director honoured, or published significant formal responses to the Request for Cancer Research at the beginning of articles, in 2010 — in particular, Tender that had been issued mid-year. January 2010, succeeding Professor Professors Mark Smyth, Joe Sambrook Our research staff worked closely with David Bowtell, who returned to full-time and Joe Trapani; Associate Professors the Department of Health’s Project Team research having completed his second Grant McArthur, Danny Rischin and and with the three consortia in working five year term in December 2009. Scott Williams and Dr Mark Shackleton, through many and varied design options. Professor Trapani was well supported amongst others. Dr Hollie Pegram Whilst very time consuming, this was during a year of strategic, funding, was awarded the 2010 Peter Mac also a very stimulating and rewarding space and other operational challenges Postgraduate Research Medal. process — in which our research staff by Assistant Directors: Associate have a clear interest. Professors Ricky Johnstone and Grant McArthur; Chief Operating Officer: Mary At the time of writing, we await a Harney and the Group Leaders. I am decision on the procurement method. very grateful for all their support, advice Craig Bennett Building work is due to be completed and guidance. Chief Executive Officer in late 2015. CEO’s report 5 Introducing our new Director Director’s report ‘The next decade holds the promise of many more targeted therapies and the hope that ultimately, cancer therapy will be individualised according to the molecular profile of that patient’s own disease. This will mean people living longer and fuller lives with cancer, a greater hope of total cure and an overall reduction in the impact of many cancers on patients and their carers.’ Professor Joseph A. Trapani MBBS, FRACP, FFSc(RCPA), PhD Professor Joseph A. Trapani Executive Director, Cancer Research New Director, new directions Among Joe’s research interests are Joe has received many personal In January 2010, I was greatly Immunology and the founding of A recurrent theme in this report is Following an extensive international the cellular and molecular biology awards and prizes including the 2008 honoured to commence a five year Platform Technologies to rival the that the recent massive technological search, Professor Joe Trapani was of cancer cell death induced by the National Health and Medical Research term as the third Executive Director best in the country. Remarkably, an achievements in molecular medicine appointed the Executive Director Cancer immune system, the immunopathology Council Award for Research Excellence of Research at Peter Mac. independent assessment of the impact and genomics find us at the dawn of viral and auto-immune diseases and the 2009 GSK Research Excellence of cancer research publications between of personalised diagnosis and Research at Peter Mac in January 2010, When offered the appointment, and adoptive immunotherapy of cancer. Award, which he shared with long-term 1981 and 2006 (ISI) saw Peter Mac treatment for many cancers.
Load more

Recommended publications
  • Patterns, Paradoxes and Personalities Medical History Museum, University of Melbourne the Story of Cancer Is Complex and Extremely Personal
    THE cancer puzzle patterns, paradoxes and personalities Medical History Museum, University of Melbourne The story of cancer is complex and extremely personal. One in two Australian men and one in three Australian women will be diagnosed with cancer by the age of 85. For generations, doctors and researchers have been searching for remedies for this disease, which has long been shrouded in fear and dread. While surgery, radiotherapy and chemotherapy are still the main treatments, radically new approaches and technologies are emerging, together with a much more sophisticated understanding of the causes and very nature of cancer. Central to the story of cancer in Victoria has been the contribution of the University of Melbourne, in undertaking fundamental and applied research, developing treatments, training clinicians and scientists, educating the public, and advocating for change. Significant figures in the Melbourne Medical School, such as Professor Peter MacCallum, have helped build the infrastructure that underpins cancer services for the Victorian community. The cancer puzzle: Patterns, paradoxes and personalities explores the roles of individuals, public education campaigns and research efforts, as well as revealing patients’ insights through the work and writings of three contemporary artists who have cancer. the cancer puzzle PATTERNS, PARADOXES AND PERSONALITIES Edited by Jacqueline Healy Medical History Museum University of Melbourne Contents Foreword vii Published 2017 by the Medical History Museum, The exhibition The cancer puzzle: Patterns, paradoxes and personalities, Professor Mark Cook Faculty of Medicine, Dentistry and Health Sciences, curated by Dr Jacqueline Healy, was held at the Medical History University of Melbourne, Victoria, 3010, Australia Museum, University of Melbourne, from 1 August 2017 to Sponsor’s message ix 24 February 2018.
    [Show full text]
  • The Role of Yoga in the Complementary Treatment of Cancer
    MOJ Yoga & Physical Therapy Mini Review Open Access The role of Yoga in the complementary treatment of cancer Abstract Volume 2 Issue 3 - 2017 The life of a cancer patient is complicated by a litany of physical, psychological, social 1 2 and spiritual factors leading to anxiety, fatigue, depression and several other unpleasant Neil K Agarwal, Shashi K Agarwal 1 emotional issues. Nausea and vomiting, insomnia and pain also contribute greatly to Hahnemann University Hospital, USA 2 the overall discomfort. These symptoms often result in a significant reduction in the Center for Contemporary and Complementary Cardiology, USA quality of life. A host of non-pharmacological therapeutic interventions have been tried to alleviate this associated physical and emotional issues in cancer patients, with Correspondence: Neil K Agarwal, Hahnemann University limited success. Yoga therapy has increasingly demonstrated evidence based benefits Hospital, USA, Email [email protected] in alleviating many of these cancer-related symptoms and in greatly improving the quality of life of these patients. Received: May 10, 2017 | Published: September 18, 2017 Keywords: yoga, cancer, anxiety, depression, fatigue, nausea and vomiting, cancer pain, quality of life Introduction Results Yoga evolved over thousands of years in India. The ancient sages Search under ‘yoga and cancer’ revealed 339 citations dating developed this practice as an integrative physical, psychological and back to 1975 on PubMed. PMC revealed 2,736 full length articles. spiritual regimen
    [Show full text]
  • Therapeutic Options for Mucinous Ovarian Carcinoma
    Edinburgh Research Explorer Therapeutic options for mucinous ovarian carcinoma Citation for published version: Gorringe, KL, Cheasley, D, Wakefield, MJ, Ryland, GL, Allan, PE, Alsop, K, Amarasinghe, KC, Ananda, S, Bowtell, DDL, Christie, M, Chiew, Y, Churchman, M, Defazio, A, Fereday, S, Gilks, CB, Gourley, C, Hadley, AM, Hendley, J, Hunter, SM, Kaufmann, SH, Kennedy, CJ, Köbel, M, Le Page, C, Li, J, Lupat, R, Mcnally, OM, Mcalpine, JN, Pyman, J, Rowley, SM, Salazar, C, Saunders, H, Semple, T, Stephens, AN, Thio, N, Torres, MC, Traficante, N, Zethoven, M, Antill, YC, Campbell, IG & Scott, CL 2020, 'Therapeutic options for mucinous ovarian carcinoma', Gynecologic Oncology, vol. 156, no. 3, pp. 552-560. https://doi.org/10.1016/j.ygyno.2019.12.015 Digital Object Identifier (DOI): 10.1016/j.ygyno.2019.12.015 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Gynecologic Oncology Publisher Rights Statement: This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc- nd/4.0/).Contents lists available atScienceDirectGynecologic Oncologyjournal homepage:www.elsevier.com/locate/ygyno General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation.
    [Show full text]
  • BARWON HEALTH RESEARCH REPORT 2018 Foreword
    Research Report 20 18 Contents 4 Foreword 36 Endocrinology 108 Opthamology 40 Epidemiology (EPI-Centre 109 Oral Health Services Section 1 for Healthy Ageing) 6 112 Palliative Care Overview 45 Infectious Diseases 114 Pharmacy 8 Academic Strategic Plan 48 Nursing 117 Physiotherapy 10 The Barwon Health Foundation 54 Nutritional Psychiatry (Food 118 Social Work and Future Fund And Mood Centre) 120 Speech Pathology 12 St Mary’s Library and 59 Orthopaedic Surgery Research Centre 122 Urology 63 Paediatrics (The Child Health 13 Grants Received Research Unit (CHRU) Section 5 14 Career Spotlight - Professor 65 Psychiatry (Impact SRC) 124 Mark Kotowicz Clinical Trials 78 Surgery 126 Clinical Trials Advisory 84 Career Spotlight - 16 Section 2 Committee Summary Dr Paul Talman Research Directorate And (CTAC) 2018 Barwon Health Human 128 Cardiology Research Ethics Committee 86 Section 4 130 Endocrinology/Infectious (HREC) Barwon Health Research Diseases And Pediatrics 18 Barwon Health Research Roundups 132 IMPACT Directorate 88 Aged Care 134 Intensive Care 22 Barwon Health Human 89 Anaesthesia Research Ethics 138 Oncology And Haematology Committee (HREC) 91 Barwon Medical Imaging (BMI) 25 Research Week 2017 Summary 93 Cancer Services Section 6 142 And Outcomes 96 Cardiology A Snapshot Of Australian 26 Career Spotlight - 98 Community Health Conferences Dr Greg Weeks 99 Healthlinks And 160 A Snapshot Of International Personalised Care Conferences 28 Section 3 101 Hospital Admission Risk Barwon Health/Deakin Program (HARP) 164 Section 7 University Collaborative Publications Research Groups 102 Nephrology 30 Emerging Infectious 105 Occupational Therapy Diseases (GCEID) 3 BARWON HEALTH RESEARCH REPORT 2018 Foreword Welcome to the 2018 Research Report, Barwon Health’s fourth annual edition.
    [Show full text]
  • 050125Understanding Nausea and Vomiting in Advanced Cancer
    CLINICAL knowledge Understanding nausea and vomiting in advanced cancer Author Colin Perdue, Bn, Rgn, dipn, is clinical nurse Definitions specialist in palliative medicine, Morriston Hospital, Nausea and vomiting are often regarded as a single Swansea. entity, but they are separate physiological conditions AbstrAct Perdue, C. (2005) Understanding nausea (Eckert, 2001). Nausea is an unpleasant feeling of the and vomiting in advanced cancer. Nursing Times; 101, need to vomit. It is often accompanied by autonomic 4, 32–35. symptoms such as pallor, cold sweat, salivation and tachy- Nausea and vomiting are commonly experienced by cardia (Yarbro et al, 1999). Retching is a strong involuntary people with advanced cancer. Nausea and vomiting can effort to vomit. It occurs in the presence of nausea and RefeRences have an adverse effect on a patient’s physical, psycho- often culminates in vomiting (Twycross and Back, 1998). logical and social well-being. Knowledge of the physiol- Vomiting (emesis) is the forceful expulsion of gastric con- Allan, S.G. (1999) Nausea and vomiting. ogy of nausea and vomiting will promote a rational tents through the mouth (Twycross and Back, 1998). In: Doyle, D. et al (eds) Oxford Textbook choice of treatment. Nurses also need to be aware of After an episode of vomiting, there may be a post- of Palliative Medicine. Oxford: Oxford non-pharmacological measures that can reduce these ejection phase characterised by weakness, lethargy and University Press. distressing symptoms. shivering (Allan, 1999). Vomiting may ease the sensation Baines, M. (1997) Nausea, vomiting and of nausea. It may serve a protective function by expelling intestinal obstruction.
    [Show full text]
  • Abstract Book Alfred Health Week Research Poster Display 23 – 27 October 2017
    Alfred Health Week Research Poster Display 23 – 27 October 2017 The Alfred Hospital ABSTRACT BOOK ALFRED HEALTH WEEK RESEARCH POSTER DISPLAY 23 – 27 OCTOBER 2017 RESEARCH DAY Tuesday, 24 October 2016, 12:00 PM – 1:00 PM AMREP Lecture Theatre 2017 KEYNOTE SPEAKER: The Hon. John Brumby AO Former Premier of Victoria, Chair, Foundation Committee, Global Health Alliance Melbourne; Faculty of Business and Economics, University of Melbourne “To the Bedside and Beyond: Medical Research and Victoria’s Future” 1 POSTER PRIZES Michael J Hall Memorial Prize for Respiratory Physiology Professor Daniel Czarny Prize for Allergy, Asthma and Clinical Immunology Research Lucy Battistel Prize for Allied Health Research Henrietta Law Memorial Prize for Allied Health Research Burnet Institute Prize for Infectious Diseases Research Monash Comprehensive Cancer Consortium Prize for Cancer Research Noel and Imelda Foster Prize for Cardiovascular Research Baker Heart and Diabetes Institute Prize for Cardiovascular Research Baker Heart and Diabetes Institute Prize for Diabetes Research Senior Medical Staff Prize for Basic Science/Laboratory-Based Research Senior Medical Staff Prizes for Clinical/Public Health Research Tony Charlton Prize for Cardiac Surgical Research Monash Alfred Psychiatry Research Centre Prize for Psychiatry Research The Greg Barclay Nursing Research Award The Senior Medical Staff Award 2 CONTENTS CATEGORY PAGE ALLERGY / ASTHMA / IMMUNITY 1. HOW DO THE PROXIMAL AND PERIPHERAL ASTHMATIC AIRWAYS RESPOND WHEN PROVOKED 15 DIRECTLY AND INDIRECTLY? Dharmakumara M, Stuart-Andrews C, Zubrinich C, Thompson B 2. ACINAR VENTILATION HETEROGENEITY IS INCREASED IN IDIOPATHIC PULMONARY FIBROSIS 15 (IPF) AND COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) Ellis M, Prasad J, Westall G, Thompson B 3.
    [Show full text]
  • Genomic Analysis of Low‐Grade Serous Ovarian Carcinoma To
    Journal of Pathology J Pathol 2020; 00: 000–000 ORIGINAL PAPER Published online 28 October 2020 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/path.5545 Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities Dane Cheasley1,2 , Abhimanyu Nigam1,2, Magnus Zethoven1,3, Sally Hunter2, Dariush Etemadmoghadam2, Timothy Semple4, Prue Allan5, Mark S Carey6, Marta L Fernandez6, Amy Dawson6, Martin Köbel7, David G Huntsman8, Cécile Le Page9 , Anne-Marie Mes-Masson9, Diane Provencher9, Neville Hacker10, Yunkai Gao1,2, David Bowtell11, Anna deFazio12, Kylie L Gorringe2† and Ian G Campbell1,2†* 1 Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 2 Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia 3 Bioinformatics Consulting Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 4 Molecular Genomics Core, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 5 Department of Clinical Pathology, Peter MacCallum Cancer Centre, and University of Melbourne, Melbourne, VIC, Australia 6 Department of Obstetrics & Gynaecology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada 7 Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada 8 Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada 9 Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM) and
    [Show full text]
  • Impact of an Allied Health Prehabilitation Service for Haematologic Patients Receiving High Dose Chemotherapy in a Large Cancer Centre
    Impact of an Allied Health Prehabilitation Service for Haematologic Patients Receiving High Dose Chemotherapy in A Large Cancer Centre Jessica Crowe ( [email protected] ) Peter MacCallum Cancer Centre https://orcid.org/0000-0002-7913-0013 Jill Francis The University of Melbourne Melbourne School of Health Sciences Lara Edbrooke Peter MacCallum Cancer Centre Jenelle Loeliger Peter MacCallum Cancer Centre Trish Joyce Peter MacCallum Cancer Centre Christina Prickett Peter MacCallum Cancer Centre Alicia Martin Peter MacCallum Cancer Centre Amit Khot Peter MacCallum Cancer Centre Linda Denehy Melbourne School of Health Sciences: The University of Melbourne Melbourne School of Health Sciences The Centre for Prehabilitation and Peri-operative Care Peter MacCallum Cancer Centre Research Article Keywords: prehabilitation, implementation, allied health, autologous stem cell transplant, high dose chemotherapy. Posted Date: June 7th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-447123/v1 Page 1/23 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 2/23 Abstract Purpose To evaluate the impact of routine multidisciplinary allied health prehabilitation care in haematologic cancer patients receiving high-dose chemotherapy with autologous stem cell transplant (AuSCT). Methods In a tertiary cancer centre, 12-months of prospectively collected data was retrospectively analysed. Patients were referred to the service for individualised exercise prescription, nutrition intervention and, if indicated through screening, psychological intervention. Impact and operational success were investigated based on the RE-AIM framework: patient uptake of the service and sample representativeness (Reach); Effectiveness in terms of changes in outcomes from initial to pre-transplant assessment; Adoption of the service by key stakeholders; delity of the prescribed exercise program (Implementation); and the extent to which the service had become part of routine standard care (Maintenance).
    [Show full text]
  • Status of Brain Imaging in Gastroparesis
    Review Status of Brain Imaging in Gastroparesis Zorisadday Gonzalez * and Richard W. McCallum Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800 Alberta Ave., El Paso, TX 79905, USA; [email protected] * Correspondence: [email protected] Received: 6 March 2020; Accepted: 7 April 2020; Published: 9 April 2020 Abstract: The pathophysiology of nausea and vomiting in gastroparesis is complicated and multifaceted involving the collaboration of both the peripheral and central nervous systems. Most treatment strategies and studies performed in gastroparesis have focused largely on the peripheral effects of this disease, while our understanding of the central nervous system mechanisms of nausea in this entity is still evolving. The ability to view the brain with different neuroimaging techniques has enabled significant advances in our understanding of the central emetic reflex response. However, not enough studies have been performed to further explore the brain–gut mechanisms involved in nausea and vomiting in patients with gastroparesis. The purpose of this review article is to assess the current status of brain imaging and summarize the theories about our present understanding on the central mechanisms involved in nausea and vomiting (N/V) in patients with gastroparesis. Gaining a better understanding of the complex brain circuits involved in the pathogenesis of gastroparesis will allow for the development of better antiemetic prophylactic and treatment strategies. Keywords: gastroparesis; brain imaging; functional magnetic resonance imaging (fMRI); positron emission tomography (PET) scan; central nervous system (CNS) 1. Introduction Gastroparesis is a chronic heterogeneous motor disorder with variable clinical manifestations including episodic nausea, vomiting, retching, post-prandial fullness, early satiety, and/or upper abdominal pain in the absence of mechanical obstruction [1].
    [Show full text]
  • Winning Over Cancer
    WINNING OVER CANCER AnnualAnnual Report Report2017 2017 1 CONTENTS During the last year, I have been overwhelmed by the outpouring of love and support that followed the news that my cancer had returned. Of course, it has been a personal challenge but OVERVIEW OUR COMMNUNITIES I feel privileged to be able to give hope to others Message from Olivia ............................................ 3 Equipment, facilities and services .............. 32 who are going through cancer. It’s a challenging and amazing journey that I have been through Chairman’s report ................................................ 4 T marks the spot .................................................34 before and I am winning over again! Year at a glance .................................................... 5 The synergy of circles ........................................36 I am grateful for and incredibly proud of the important work being done at the Olivia Directors’ report .................................................... 6 Clinician scientist fellowships ....................... 37 Newton-John Cancer Institute. It is hugely Collaborations and partnerships ................38 reassuring to know that scientists, doctors, OUR HIGHLIGHTS Students: the next generation .................... 40 volunteers and other healthcare practitioners are working around the clock to win over cancer Flicking the switch on Donors and supporters .....................................41 Message from and that they are helping so many people who colon cancer’s own killer ................................... 7 Amazing gift leaves a lasting come to the Centre for support. Reducing the costs of legacy for cancer research .............................43 our founding The ONJCRI holds a special place in my lung cancer misdiagnosis ................................. 8 heart in this regard. Medical research and Suppressing cancer cell corruption .............. 9 scientific endeavour run through my veins - OUR ORGANISATION champion, and although I chose a musical path, I am Rising to the challenge of lung cancer ...
    [Show full text]
  • 2019 Annual Report
    2019 Annual Report [TITLE] Contents Centre Director’s Message 3 Objectives 4 IMPACCT at a glance 5 Awards and achievements 6 Research projects summary 7 Chronic Breathlessness management - World first medication listed 8 Publications summary 9 Postgraduate Palliative Care Course 10 IMPACCT Team 13 ImPaCCT:NSW Team 23 Clinical Trials 23 PaCCSC and CST Team, PaCCSC Governance 24 CST Governance 26 Consumer Advisory Group 30 External Academic Appointments 30 Editorial Roles 31 UTS Committees 32 UTS Teaching and Learning 33 IMPACCT-led Grants Awarded 2019 34 Collaborative grants led by other areas or institutions awarded in 2019 35 Current Projects 36 Higher degree research students 64 Publications 67 Conference presentations 77 Collaborations 78 ITCC Clinical Trials Sites 79 Visiting Scholars 83 External Engagement 84 Approvals & Overall Comments – Centre Annual Report 87 2019 ANNUAL REPORT | IMPACCT 2 Centre Director’s Message The Centre for Improving Palliative, Aged and Chronic Care through Clinical Research and Translation (IMPACCT) takes real world problems and works collaboratively to develop feasible, affordable and effective solutions. Combining the input of our lived-experience advisors (consumers), with the insights from our clinical experts, industry partners and the depth and breadth of expertise within our academic group, ensures that our research and educational endeavours are grounded in improving what matters most to older people - those living with progressive chronic illnesses and people with palliative care needs. This year, many of IMPACCT’s academics were honoured with a variety of awards, highlighted below and showcased in the Annual Report. One of the most significant achievements was the world’s first registration of a medication to manage optimally treated breathlessness, and its subsequent addition to the pharmaceutical benefits scheme list in early 2019 was a major highlight.
    [Show full text]
  • Tumour Mutation Status and Sites of Metastasis in Patients with Cutaneous Melanoma
    FULL PAPER British Journal of Cancer (2017) 117, 1026–1035 | doi: 10.1038/bjc.2017.254 Keywords: cutaneous melanoma; melanoma; BRAF mutation; mutation status; metastasis; sentinel lymph node biopsy Tumour mutation status and sites of metastasis in patients with cutaneous melanoma Nikki R Adler*,1,2, Rory Wolfe2, John W Kelly1, Andrew Haydon1,3, Grant A McArthur4,5, Catriona A McLean1,6 and Victoria J Mar1,2,7 1Victorian Melanoma Service, Alfred Hospital, Melbourne, Victoria 3004, Australia; 2School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria 3004, Australia; 3Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria 3004, Australia; 4Divisions of Research and Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia; 5Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria 3000, Australia; 6Department of Anatomical Pathology, Alfred Hospital, Melbourne, Victoria 3004, Australia and 7Skin and Cancer Foundation, Carlton, Victoria 3053, Australia Background: Cutaneous melanoma can metastasise haematogenously and/or lymphogenously to form satellite/in-transit, lymph node or distant metastasis. This study aimed to determine if BRAF and NRAS mutant and wild-type tumours differ in their site of first tumour metastasis and anatomical metastatic pathway. Methods: Prospective cohort of patients with a histologically confirmed primary cutaneous melanoma at three tertiary referral centres in Melbourne, Australia from 2010 to 2015. Multinomial regression determined clinical, histological and mutational factors associated with the site of first metastasis and metastatic pathway. Results: Of 1048 patients, 306 (29%) developed metastasis over a median 4.7 year follow-up period. 73 (24%), 192 (63%) and 41 (13%) developed distant, regional lymph node and satellite/in-transit metastasis as the first site of metastasis, respectively.
    [Show full text]